Eli Lilly (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals said today that its insulin glargine injection, Basaglar, is available by prescription in the U.S. Basaglar is a long-acting insulin with the same amino acid sequence as Sanofi‘s (NYSE:SNY) Lantus. The companies also offer resources for patients beginning insulin treatment, including an app for smartphones and tablets which provides […]
Pharmaceuticals
Ex pharma execs first to be charged in generic drug pricing case
Former Heritage Pharmaceuticals CEO Jeffrey Glazer and ex-president Jason Malek were hit yesterday with the 1st criminal charges from a 2-year federal investigation in an ongoing generic drug pricing case. The 2 former executives were charged by federal authorities with price collusion for doxycycline hyclate, a widely used antibiotic, and a diabetes therapy called glyburide […]
Baxter to put up $625m for Claris Injectables generics biz
Baxter (NYSE:BAX) said today that acquired Claris Lifesciences (BOM:533288) subsidiary Claris Injectables for $625 million. The deal is expected to close in the 2nd half of next year. Deerfield, Ill.-based Baxter said it plans to pay for the acquisition with cash on hand, debt or a combination. Baxter anticipates launching 7 to 9 new products […]
BD launches high volume syringe for biologics
Becton Dickinson (NYSE:BDX) said today that it launched its BD Neopak 2.25 milliliter prefillable glass syringe designed for high-volume injection of biologics. The Franklin Lakes, N.J.-based company said that its prefillable glass syringe was developed to reduce drug degradation and aggregation between the container and therapeutic. The high volume syringe is commercially available in the […]
TiGenix IPO raises $36m
TiGenix (EBR:TIG) said today that it raised $36 million in an initial public offering from the sale of 2.3 million American depository shares, representing 46 million ordinary shares, at $15.50 apiece. The biopharmaceutical company plans to list on the NASDAQ exchange under the “TIG” symbol by Dec. 15. It is listed on the Euronext Brussels under the same symbol. […]
BioDelivery names Ginsberg as biz dev veep | Personnel Moves, Dec. 14, 2016
BioDelivery Sciences International (NSDQ:BDSI) said today that it named Peter Ginsberg as its VP of business development. Prior to joining the Raleigh, N.C.-based company, Ginsberg led business development at United Therapeutics and directed a $350 million sale of the company’s priority review voucher. He has also served as VP of business & technology development for […]
AARP report details increase in brand name drug prices
The AARP Public Policy Institute released a report today showing that 2015 was the 4th straight year of double-digit average annual increases for widely used brand name drugs. The nonprofit organization also concluded that prices for brand name drugs increased almost 130 times faster than the 0.1% general inflation rate in 2015. The report, which […]
AcelRx seeks FDA nod for non-invasive sufentanil painkiller
AcelRx Pharmaceuticals (NSDQ:ACRX) said today that it submitted a new drug application to the FDA for its ARX-04 sublingual sufentanil tablet. The non-invasive compound has been studied as a treatment for patients experiencing moderate or severe acute pain and is administered in a medically supervised setting using a disposable, pre-filled, single-dose applicator. The Redwood City, Calif.-based […]
Adherium’s smart inhaler tech chosen for EU mobile health program
Adherium Ltd. (ASK:ADR) said today that its Smartinhaler was chosen for the myAirCoach program as a part of the European Union’s Horizon 2020 Framework for Research and Innovation. The Horizon 2020 program is the largest EU research and innovation program ever established, with €80 billion (nearly $85 billion) of funding available from 2014 until 2020. The […]
Federal watchdog to investigate CMS drug rebate program
The Office of the Inspector General of the Health and Human Services Departments said last week that it will begin investigating whether the Centers for Medicare & Medicaid Services properly monitors its Medicaid Drug Rebate Program. The investigation comes after CMS reported that Mylan (NSDQ:MYL) underpaid Medicaid by not paying appropriate rebates. The Canonsburg, Penn.-based company said […]
